CHIMERIX INCCMRX

時価総額
$8173.5万
PER
2013年
12月31日
2014年
12月31日
2015年
12月31日
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
2023年
12月31日
Net income (loss)-36-59-117-76-71-69-113-44-173172-82
Depreciation00111110000
Amortization of debt issuance costs000------00
Amortization of discount/premium on investments-0-1-2-10120-127
Share-based compensation3413161613106121517
Fair value of common stock issued related to asset acquisition--------43--
Note payable related to asset acquisition--------14--
Gain on sale of TEMBEXA---------230-
Gain on sale of equipment----------0
Gain on sale of investments------0-0000-
Lease-related amortization--------00-0
Accounts receivable-1-02-10-11-1-01-1
Inventories--------32-
Prepaid expenses and other assets203-30-11-125-3
Accounts payable and accrued liabilities268-1030-4-076-2
Net cash used in operating activities-26-47-100-64-50-54-75-36-100-47-69
Net cash used in operating activities-26-47-100-64-50-54-75-36-100-47-69
Purchases of property and equipment01210000000
Purchases of short-term investments21556024-1261687410518390
Purchases of long-term investments-55235791636--105839
Proceeds from Sale of Short-Term Investments131-14111131748-
Proceeds from maturities of short-term investments11491271981661261651216769199
Proceeds from sale of TEMBEXA---------234-
Proceeds from sale of property and equipment-------0--0
Net cash provided by (used in) investing activities9-160-16994161051165-447071
Proceeds from Stock Options Exercised2520000141-
Proceeds from employee stock purchase plan-0101100110
Proceeds from Issuance of Common Stock--162--11--108--
Payments of deferred offering costs----000--0-
Payments of debt issuance costs----------0
Payment of note payable----------14-
Net cash provided by (used in) financing activities106225161111101112-130
Net increase (decrease) in cash and cash equivalents-------6430-32102
Non-cash purchases of property and equipment-------0---